Skip to main content
Erschienen in: International Urogynecology Journal 10/2013

01.10.2013 | Review Article

Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review

verfasst von: S. Rachaneni, P. Arya, P. Latthe

Erschienen in: International Urogynecology Journal | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

Nerve growth factor (NGF) is a signalling protein that interacts with specific receptors in autocrine, paracrine and endocrine modes. It is produced by bladder smooth muscle and urothelium. Patients with overactive bladder and detrusor overactivity (DO) have been found to have increased urinary NGF levels in several small studies. The objective of the review was to assess the accuracy of NGF as a biomarker in the diagnosis of DO by a systematic review of the literature. A systematic search of MEDLINE, Embase, CINAHL, MEDION and LILACS databases was conducted (inception till December 2012). Selection criteria included studies where NGF (as a biomarker for DO) and urodynamics were performed in humans with symptoms of overactive bladder. Two reviewers independently selected articles and extracted data on study characteristics, quality and results. All the eight included studies were of case-control design. A meta-analysis was not performed as there were variations in the quality, methods of performing the NGF assay, different NGF cut-offs used and the format of reporting findings. Two studies used a cut-off of 0.05 for NGF levels. Six studies observed a trend towards higher NGF levels in patients with DO. There was a trend towards higher NGF in patients with DO. However, the data are imprecise and hence cannot be recommended for use in current clinical practice.
Literatur
1.
Zurück zum Zitat Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26PubMedCrossRef Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 21(1):5–26PubMedCrossRef
2.
Zurück zum Zitat Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314PubMedCrossRef Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314PubMedCrossRef
3.
Zurück zum Zitat Steers WD (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4(Suppl 4):S7–S18PubMed Steers WD (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4(Suppl 4):S7–S18PubMed
4.
5.
Zurück zum Zitat Digesu GA, Khullar V, Cardozo L, Salvatore S (2003) Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003(22):105–108CrossRef Digesu GA, Khullar V, Cardozo L, Salvatore S (2003) Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003(22):105–108CrossRef
6.
Zurück zum Zitat Foon R, Toozs-Hobson P, Latthe P (2012) Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies. Cochrane Database Syst Rev 10:CD008224 Foon R, Toozs-Hobson P, Latthe P (2012) Prophylactic antibiotics to reduce the risk of urinary tract infections after urodynamic studies. Cochrane Database Syst Rev 10:CD008224
7.
Zurück zum Zitat Vizzard MA (2000) Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 161:273–284PubMedCrossRef Vizzard MA (2000) Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 161:273–284PubMedCrossRef
8.
Zurück zum Zitat Yoshimura N (1999) Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol 57:583–606PubMedCrossRef Yoshimura N (1999) Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of the urinary bladder. Prog Neurobiol 57:583–606PubMedCrossRef
9.
Zurück zum Zitat Lamb K, Gebhart GF, Bielefeldt K (2004) Increased nerve growth factor expression triggers bladder overactivity. J Pain 5:150–156PubMed Lamb K, Gebhart GF, Bielefeldt K (2004) Increased nerve growth factor expression triggers bladder overactivity. J Pain 5:150–156PubMed
10.
Zurück zum Zitat Kuo HC, Liu HT, Chancellor MB (2010) Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol 12:e69–e77PubMed Kuo HC, Liu HT, Chancellor MB (2010) Can urinary nerve growth factor be a biomarker for overactive bladder? Rev Urol 12:e69–e77PubMed
11.
Zurück zum Zitat Khan KS, Dinnes J, Kleijnen J (2001) Systematic reviews to evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol 95:6–11PubMedCrossRef Khan KS, Dinnes J, Kleijnen J (2001) Systematic reviews to evaluate diagnostic tests. Eur J Obstet Gynecol Reprod Biol 95:6–11PubMedCrossRef
12.
Zurück zum Zitat Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25PubMedCrossRef Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25PubMedCrossRef
13.
Zurück zum Zitat Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175:1773–1776PubMedCrossRef Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175:1773–1776PubMedCrossRef
14.
Zurück zum Zitat Vijaya G, Gallo P, Derpapas A, Cartwright R, Digesu G, Dell’utri C et al (2011) Increased nerve growth factor in overactive bladder: is it caused by infection? Int Urogynecol J 22:S187–S188 (Conference abstract) Vijaya G, Gallo P, Derpapas A, Cartwright R, Digesu G, Dell’utri C et al (2011) Increased nerve growth factor in overactive bladder: is it caused by infection? Int Urogynecol J 22:S187–S188 (Conference abstract)
15.
Zurück zum Zitat Liu HT, Chancellor MB, Kuo HC (2008) Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 102:1440–1444PubMed Liu HT, Chancellor MB, Kuo HC (2008) Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int 102:1440–1444PubMed
16.
Zurück zum Zitat Kuo HC, Liu HT, Chancellor MB (2010) Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 29:482–487PubMed Kuo HC, Liu HT, Chancellor MB (2010) Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol Urodyn 29:482–487PubMed
17.
Zurück zum Zitat Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681–1685PubMedCrossRef Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106:1681–1685PubMedCrossRef
18.
Zurück zum Zitat Yokoyama T, Kumon H, Nagai A (2008) Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 27:417–420PubMedCrossRef Yokoyama T, Kumon H, Nagai A (2008) Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol Urodyn 27:417–420PubMedCrossRef
19.
Zurück zum Zitat Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179:2270–2274PubMedCrossRef Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179:2270–2274PubMedCrossRef
20.
Zurück zum Zitat Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 12:875–880PubMedCrossRef Kim JC, Park EY, Hong SH, Seo SI, Park YH, Hwang TK (2005) Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol 12:875–880PubMedCrossRef
21.
Zurück zum Zitat Jacobs BL, Smaldone MC, Tyagi V, Philips BJ, Jackman SV, Leng WW et al (2010) Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol 17:4989–4994PubMed Jacobs BL, Smaldone MC, Tyagi V, Philips BJ, Jackman SV, Leng WW et al (2010) Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol 17:4989–4994PubMed
22.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535PubMedCrossRef
23.
Zurück zum Zitat Vijaya G, Cartwright R, Digesu G et al (2011) Can urinary nerve growth factor (NGF) replace urodynamics to diagnose lower urinary tract symptoms? Int Urogynecol J 22:S20–S21 (Conference abstract) Vijaya G, Cartwright R, Digesu G et al (2011) Can urinary nerve growth factor (NGF) replace urodynamics to diagnose lower urinary tract symptoms? Int Urogynecol J 22:S20–S21 (Conference abstract)
24.
Zurück zum Zitat Seth JH, Sahai A, Khan MS et al (2013) Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int 111:372–380PubMedCrossRef Seth JH, Sahai A, Khan MS et al (2013) Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int 111:372–380PubMedCrossRef
25.
Zurück zum Zitat Seth J, Sahai A, Oppenheim M, Dasgupta P, Panicker J, Fowler C (2012) Urinary nerve growth factor in neurogenic bladder dysfunction. J Endourol 26(A/23):887–892 Seth J, Sahai A, Oppenheim M, Dasgupta P, Panicker J, Fowler C (2012) Urinary nerve growth factor in neurogenic bladder dysfunction. J Endourol 26(A/23):887–892
26.
Zurück zum Zitat Birder LA, Wolf-Johnston A, Griffiths D, Resnick NM (2007) Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 26:405–409PubMedCrossRef Birder LA, Wolf-Johnston A, Griffiths D, Resnick NM (2007) Role of urothelial nerve growth factor in human bladder function. Neurourol Urodyn 26:405–409PubMedCrossRef
Metadaten
Titel
Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review
verfasst von
S. Rachaneni
P. Arya
P. Latthe
Publikationsdatum
01.10.2013
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 10/2013
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-013-2104-0

Weitere Artikel der Ausgabe 10/2013

International Urogynecology Journal 10/2013 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.